Document is current
Any future updates will be listed below
-
Authors
Liu, Stephen V. https://orcid.org/0000-0002-4852-3914
Elkins, Ivy B.
Feldman, Jill
Goldberg, Sarah B.
-
Funding
Funding for this research was provided by:
Daiichi-Sankyo
- License Information
-
More Information
Article History
Received: 23 November 2022
Accepted: 23 August 2023
First Online: 26 September 2023
Declarations
:
: Stephen V. Liu has received research grants to his institution from Alkermes, Bayer, Blueprint Medicines, Bristol Myers Squibb, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, Pfizer, RAPT Therapeutics, and Turning Point Therapeutics; has received personal consulting fees from Amgen, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, MSD, Novartis, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics; and has participated on a data safety monitoring board for Candel Therapeutics. Ivy B. Elkins has received consulting fees from AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Gilead, Janssen, Merck, and Sanofi. Jill Feldman has received consulting fees from AstraZeneca, Blueprint Medicines, Janssen, Takeda, Novartis, and EQRx. Sarah B. Goldberg has received grants or contracts from Mirati Therapeutics, AstraZeneca, and Boehringer Ingelheim; has received personal consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Amgen, Blueprint Medicines, Sanofi, Daiichi Sankyo, Regeneron, Takeda, and Janssen; has received honoraria for lectures from Amgen and AstraZeneca; and has participated on a data safety monitoring board for Daiichi Sankyo.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
